Glenview Trust Co Buys 2,990 Shares of Cigna Group $CI

Glenview Trust Co boosted its stake in shares of Cigna Group (NYSE:CI) by 16.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,777 shares of the health services provider’s stock after acquiring an additional 2,990 shares during the quarter. Glenview Trust Co’s holdings in Cigna Group were worth $5,542,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Cigna Group by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 26,173,577 shares of the health services provider’s stock worth $7,203,754,000 after purchasing an additional 414,834 shares in the last quarter. State Street Corp boosted its position in Cigna Group by 1.8% in the fourth quarter. State Street Corp now owns 12,339,250 shares of the health services provider’s stock valued at $3,396,132,000 after buying an additional 224,122 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its position in Cigna Group by 8.3% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 11,805,083 shares of the health services provider’s stock valued at $3,249,113,000 after buying an additional 903,334 shares in the last quarter. Dodge & Cox grew its stake in Cigna Group by 19.7% during the fourth quarter. Dodge & Cox now owns 11,138,614 shares of the health services provider’s stock worth $3,065,681,000 after buying an additional 1,833,389 shares during the last quarter. Finally, GQG Partners LLC grew its stake in Cigna Group by 14.3% during the fourth quarter. GQG Partners LLC now owns 7,763,295 shares of the health services provider’s stock worth $2,136,699,000 after buying an additional 972,302 shares during the last quarter. 86.99% of the stock is owned by institutional investors.

Cigna Group Stock Performance

Cigna Group stock opened at $289.82 on Wednesday. The company has a current ratio of 0.73, a quick ratio of 0.73 and a debt-to-equity ratio of 0.69. Cigna Group has a 1 year low of $239.51 and a 1 year high of $315.47. The company has a market cap of $76.67 billion, a PE ratio of 12.29, a PEG ratio of 1.09 and a beta of 0.29. The company’s 50-day moving average is $286.41 and its two-hundred day moving average is $280.59.

Cigna Group (NYSE:CI) last announced its quarterly earnings results on Thursday, April 30th. The health services provider reported $7.79 EPS for the quarter, beating analysts’ consensus estimates of $7.60 by $0.19. The company had revenue of $68.52 billion during the quarter, compared to analysts’ expectations of $66.29 billion. Cigna Group had a return on equity of 19.75% and a net margin of 2.26%.Cigna Group’s revenue was up 4.6% on a year-over-year basis. During the same period in the prior year, the business posted $6.74 EPS. Cigna Group has set its FY 2026 guidance at 30.350- EPS. Equities analysts anticipate that Cigna Group will post 30.39 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft cut shares of Cigna Group from a “buy” rating to a “hold” rating and cut their target price for the company from $303.00 to $302.00 in a research note on Wednesday, May 20th. Weiss Ratings restated a “hold (c)” rating on shares of Cigna Group in a research report on Monday, June 1st. Wall Street Zen raised Cigna Group from a “hold” rating to a “buy” rating in a report on Saturday, June 20th. Royal Bank Of Canada lifted their price objective on Cigna Group from $333.00 to $337.00 and gave the company an “outperform” rating in a research report on Friday, May 1st. Finally, Guggenheim boosted their price objective on Cigna Group from $334.00 to $338.00 and gave the stock a “buy” rating in a research note on Monday, May 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $338.80.

Insider Buying and Selling at Cigna Group

In other news, CEO David Cordani sold 201,878 shares of the stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $292.82, for a total transaction of $59,113,915.96. Following the completion of the sale, the chief executive officer owned 34,337 shares of the company’s stock, valued at $10,054,560.34. This represents a 85.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Jamie G. Kates sold 899 shares of the business’s stock in a transaction on Friday, June 12th. The shares were sold at an average price of $298.61, for a total transaction of $268,450.39. Following the completion of the sale, the chief accounting officer directly owned 2,368 shares in the company, valued at $707,108.48. This represents a 27.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 0.60% of the stock is owned by corporate insiders.

About Cigna Group

Cigna Group (NYSE: CI) is a global health services company that offers a broad portfolio of healthcare products and insurance solutions for individuals, employers, and governments. Its core businesses include medical and behavioral health plans, dental and vision coverage, pharmacy benefit management, and supplemental health products. Cigna serves a mix of commercial, Medicare, and Medicaid customers and provides workplace benefits such as group health plans and disability and life benefits for employers.

In addition to traditional insurance products, Cigna operates health services and care-delivery platforms designed to manage costs and improve outcomes.